TY - JOUR T1 - Sacubitril, valsartan and SARS-CoV-2 JF - BMJ Evidence-Based Medicine JO - BMJ EBM SP - 205 LP - 205 DO - 10.1136/bmjebm-2020-111497 VL - 26 IS - 4 AU - Antonio Vitiello AU - Raffaele La Porta AU - Francesco Ferrara Y1 - 2021/08/01 UR - http://ebm.bmj.com/content/26/4/205.abstract N2 - Dear Editor,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (COVID-19) is responsible for the current global pandemic. To date, no antivirals directed against the virus or effective vaccines are available.1 It is essential to recognise the risk factors and components that may play a protective role. There is no clear evidence on the correlation between changes in the renin–angiotensin system (RAS) by treatment with ACEIs, ARBs or DRis and COVID-19 infection.2–4 Randomised controlled trials are needed to verify the involvement of COVID-19 viral infection and chronic treatment with these drugs. A possible scientific hypothesis to investigate is the … ER -